FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

仅供研究使用。 完整免责声明 →

堆栈库

Longevity Optimizer

Anti-Aging & Longevityadvanced
22
Share
肽类

4

平均每日mcg

13,643

级别

advanced

添加时间

May 16, 2026

概述

The Longevity Optimizer is a comprehensive, advanced-tier anti-aging protocol that targets the four major axes of biological aging: telomere attrition, mitochondrial decline, immune senescence, and extracellular matrix degradation. This four-peptide stack represents one of the most complete longevity interventions available, combining Epithalon for chromosomal maintenance, MOTS-c for mitochondrial optimization, Thymosin Alpha-1 for immune rejuvenation, and GHK-Cu for tissue remodeling and gene expression modulation. Epithalon at 10000mcg daily activates telomerase to maintain and potentially restore telomere length, directly addressing the Hayflick limit that constrains cellular replication capacity. MOTS-c at 5000mcg every other day is a mitochondria-derived peptide that enhances cellular energy metabolism, improves insulin sensitivity, activates AMPK pathways, and promotes metabolic homeostasis, effectively rejuvenating the cellular powerhouses that decline with age. Thymosin Alpha-1 at 1500mcg three times per week restores thymic function and T-cell diversity, combating the immunosenescence that leaves aging individuals vulnerable to infections and cancer. GHK-Cu at 500mcg daily is a naturally occurring copper-binding tripeptide that remodels damaged collagen, activates over 4,000 genes toward a healthier expression pattern, provides potent antioxidant activity, and supports skin, organ, and connective tissue integrity. The synergy across these four peptides is multiplicative: cells that maintain their telomeres, power their mitochondria efficiently, remain under competent immune surveillance, and exist within healthy extracellular matrix age far more slowly than those lacking any single component. Administer Epithalon and GHK-Cu in the morning. MOTS-c is best taken on non-consecutive days, ideally before physical activity to leverage its exercise-mimetic properties. Thymosin Alpha-1 should be administered on fixed days (e.g., Monday, Wednesday, Friday). This stack is designed for committed biohackers and advanced users over 35 who prioritize healthspan extension and biological age reversal. Users should establish baseline longevity biomarkers including telomere length, DNA methylation age (epigenetic clocks), inflammatory panels, and mitochondrial function tests. Research backing each component spans decades, from Khavinson longevity studies on Epithalon to recent MOTS-c metabolic research and extensive GHK-Cu gene expression data. Cycle 12-16 weeks with physician oversight.

给药方案

10,000 mcg

每剂

MOTS-c

Every other day

了解更多关于MOTS-c →

5,000 mcg

每剂

Thymosin Alpha-1

3 times per week

了解更多关于Thymosin Alpha-1 →

1,500 mcg

每剂

500 mcg

每剂

目标与证据

证据等级:community

Comments

Sign in to join the discussion

免责声明: 此堆栈由社区提交,仅供研究用途。Peptide Contacts不对提交的堆栈的安全性或有效性进行验证。使用任何肽类协议前,请务必咨询合格的医疗专业人员。